Brief: Revelation Biosciences Inc. Announces Positive Results In Preclinical Model Of Acute And Chronic Kidney Disease

Revelation Biosciences

25/10/2022 14:01

Oct 25 (Reuters) - Revelation Biosciences Inc  REVB.O :
    * REVELATION BIOSCIENCES INC. ANNOUNCES POSITIVE RESULTS IN
PRECLINICAL MODEL OF ACUTE AND CHRONIC KIDNEY DISEASE
    * REVELATION BIOSCIENCES INC - PHASE 1 CLINICAL STUDY
PLANNED FOR
1H 2023
    * REVELATION BIOSCIENCES INC. ANNOUNCES POSITIVE RESULTS IN
PRECLINICAL MODEL OF ACUTE AND CHRONIC KIDNEY DISEASE
    * REVELATION BIOSCIENCES INC - TREATMENT WITH REVTX-300
SIGNIFICANTLY REDUCED RENAL CORTICAL FIBROSIS IN A DOSE
DEPENDENT MANNER
    * REVELATION BIOSCIENCES INC - ADDITIONAL MODELS OF FIBROTIC
DISEASES INCLUDING AKI, CKD, NASH, AND MYOCARDITIS TO COMMENCE
IN Q4 2022
    * REVELATION BIOSCIENCES INC - ADDITIONAL MODELS OF FIBROTIC
DISEASES INCLUDING AKI, CKD, NASH, AND MYOCARDITIS TO COMMENCE
IN Q4 2022
    * REVELATION BIOSCIENCES INC - PHASE 1 CLINICAL STUDY
PLANNED FOR
1H 2023

Source text for Eikon:  ID:nBw1pywWsa 
Further company coverage:  REVB.O 
 ((Reuters.Briefs@thomsonreuters.com;;))